Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348163 · ClinicalTrials.gov registry record · Phase 4
(mo)BETTA Trial in Transwomen for Optimization of ART
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT03348163: Clinical Trial Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
NCT03348163 is a Phase 4 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03348163, a Phase 4 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
Primary Outcome
Number of participants who maintain \<50 copies/mL HIV-1 RNA for 48 weeks
Interventions
- DRUG B/FTC/TAF
- DRUG Current ART
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2020-12-15 |
| Phase | Phase 4 |
Why NCT03348163 stopped before completion
NCT03348163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which B/FTC/TAF is the first listed.
NCT03348163 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03348163 about?
NCT03348163 is a clinical study titled "(mo)BETTA Trial in Transwomen for Optimization of ART". The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected transgender women (TW).
What is the current status of trial NCT03348163?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2018-06-06. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT03348163?
The interventions under investigation include: B/FTC/TAF (DRUG), Current ART (DRUG).
Who is sponsoring clinical trial NCT03348163?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03348163's enrollment target sits among peer trials
26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI